Skip to main content
Clinical Trials

A Phase 2 Study of the Hepcidin Mimetic PTG-300 in Patients with Phlebotomy-Requiring Polycythemia Vera (CTMS# 19-0038) IRB: Advarra

Cancer Type

Other

ClinicalTrials.gov Identifier

NCT04057040

Principal Investigator

Ruben Mesa M.D.

For more information about this study
View Details

About This Study

This is a Phase 2 study with an open-label dose escalation phase followed by a blinded withdrawal phase and an open label extension. The study is designed to monitor the PTG-300 safety profile and to obtain preliminary evidence of efficacy of PTG-300 for the treatment of phlebotomy-requiring polycythemia vera.